Global licensing opportunities

ORP-102 is a metabolically stable, non-systemic full antagonist of the μ opioid receptor. The dimer is designed to mitigate abdominal distress following chronic exposure to systemic opioids.

ORP-103 is a metabolically stable modulator of intestinal serotonin and norepinephrine to address intestinal motility disorders.

ORP-104 is a metabolically stable β2-adrenergic receptor agonist for oral treatment of asthma and COPD.

ORP-106 is an inverse μ agonist for treatment of opioid and alcohol addiction.